Orchestra BioMed, Inc. has appointed Dennis Donohoe, M.D., as chief medical officer. Dr. Donohoe is a leading clinical development expert with an outstanding track record of success in steering high-impact therapeutic devices through clinical trials and regulatory approvals, including the CYPHER® sirolimus-eluting stent, the first FDA approved drug-eluting stent, for which he oversaw global registrational clinical development during his tenure as worldwide vice president of clinical, regulatory and medical affairs for Cordis Corporation (a Johnson & Johnson Company).
 
“Dennis Donohoe is a proven leader with extensive clinical and regulatory experience directly relevant to our therapeutic device product pipeline. We are thrilled that Dennis has agreed to join our management team on a full-time basis,” said David Hochman, chairman and chief executive officer of Orchestra BioMed. “We could not ask for a more qualified leader as we prepare to initiate a global clinical and regulatory development program focused on multiple coronary and peripheral indications for Virtue® SEB in collaboration with Terumo, our strategic partner. His extensive knowledge and expertise will also be vital to further our clinical and regulatory plans for BackBeat CNT for hypertension, our other flagship product, as well as additional pipeline development initiatives we expect to embark on in the future.”